Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.
Michael J. Morris, MD
Advertisement
Articles by Michael J. Morris, MD
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Advertisement
Latest Updated Articles
Michael J. Morris, MD, on Future Directions of PSMA Imaging in Prostate CancerPublished: July 3rd 2020 | Updated:
CHAARTED: ADT Plus Docetaxel in Prostate CancerPublished: June 30th 2014 | Updated:
Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate CancerPublished: June 4th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
3
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
4
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
5
